Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
June 18, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
March 13, 2018 14:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it...
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
March 12, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an...
Crinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
March 07, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer
January 04, 2018 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 02, 2018 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Chiasma Recognizes Acromegaly Awareness Day
November 01, 2017 08:50 ET
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
October 26, 2017 10:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...
Crinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s Disease
September 06, 2017 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...
Strongbridge Biopharma plc Provides Updates on KEVEYIS® Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results
August 07, 2017 07:00 ET
|
Strongbridge Biopharma plc
~ Launched KEVEYIS® (dichlorphenamide) to U.S. Primary Periodic Paralysis Community, Established Strongbridge CareConnection Patient Services and Support Program, and Mobilized 12-Person...